Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial

Irene García-García, Enrique Seco-Meseguer, Pilar Ruiz-Seco, Gema Navarro-Jimenez, Raúl Martínez-Porqueras, María Espinosa-Díaz, Juan José Ortega-Albás, Iñigo Sagastagoitia, María Teresa García-Morales, María Jiménez-González, Lucía Martínez de Soto, Ana Isabel Bajo-Martínez, María Del Palacio-Tamarit, Raquel López-García, Lucía Díaz-García, Javier Queiruga-Parada, Christine Giesen, Ana Pérez-Villena, Marta de Castro-Martínez, Juan J. González-GarcíaMiguel Rodriguez-Rubio, Pedro de la Oliva, José R. Arribas, Antonio J. Carcas, Alberto M. Borobia

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We evaluated in this randomised, double-blind clinical trial the efficacy of melatonin as a prophylactic treatment for prevention of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure. Healthcare workers fulfilling inclusion criteria were recruited in five hospitals in Spain and were randomised 1:1 to receive melatonin 2 mg administered orally for 12 weeks or placebo. The main outcome was the number of SARS-CoV-2 infections. A total of 344 volunteers were screened, and 314 were randomised: 151 to placebo and 163 to melatonin; 308 received the study treatment (148 placebo; 160 melatonin). We detected 13 SARS-CoV-2 infections, 2.6% in the placebo arm and 5.5% in the melatonin arm (p = 0.200). A total of 294 adverse events were detected in 127 participants (139 in placebo; 155 in melatonin). We found a statistically significant difference in the incidence of adverse events related to treatment: 43 in the placebo arm and 67 in the melatonin arm (p = 0.040), and in the number of participants suffering from somnolence related to treatment: 8.8% (n = 14) in the melatonin versus 1.4% (n = 2) in the placebo arm (p = 0.008). No severe adverse events related to treatment were reported. We cannot confirm our hypothesis that administration of melatonin prevents the development of SARS-CoV-2 infection in healthcare workers.

Original languageEnglish
Article number1139
JournalJournal of Clinical Medicine
Volume11
Issue number4
DOIs
StatePublished - 1 Feb 2022
Externally publishedYes

Keywords

  • COVID-19
  • Healthcare workers
  • Melatonin
  • Prophylaxis
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial'. Together they form a unique fingerprint.

Cite this